Effect of bradykinin-receptor blockade on the response to angiotensin- converting-enzyme inhibitor in normotensive and hypertensive subjects

New England Journal of Medicine

Volumn 339, Issue 18, 1998, Pages 1285-1292

  Gainer, James V ^a   Morrow, Jason D ^a   Loveland, Angela ^a   King, Debbie J ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; LOSARTAN POTASSIUM;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; KIDNEY VASCULAR RESISTANCE; MALE; NATRIURESIS; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; SINGLE BLIND PROCEDURE; SODIUM DEPLETION; URINE VOLUME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYKININ; CAPTOPRIL; DIET, SODIUM-RESTRICTED; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; LOSARTAN; MALE; RECEPTORS, BRADYKININ; REFERENCE VALUES; RENIN-ANGIOTENSIN SYSTEM; SINGLE-BLIND METHOD;

EID: 0032578789     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199810293391804     Document Type: Article

References (42)

1. Erdos EG. The angiotensin I converting enzyme. Fed Proc 1977;36: 1760-5.
2. Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978;298:991-5.
3. Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnic JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int 1981;20:240-5.
4. Navis G, de long PE, Donker AJM, van der Hem GK, de Zeeuw D. Effects of enalaprilic acid on sodium excretion and renal hemodynamics in essential hypertension. J Clin Hypertens 1985;1:228-38.
5. Mimran A, Brunner HR, Turini GA, Waeber B, Brunner D. Effect of captopril on renal vascular tone in patients with essential hypertension. Clin Sci 1979;57:Suppl 5:421S-423S.
6. Vanhoutte PM. Endothelium and control of vascular function: state of the art lecture. Hypertension 1989;13:658-67.
7. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest 1980;65:1257-64.
8. Johnston C, Millar J, McGrath BP, Matthews PG. Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. Lancet 1979;2:493-6.
9. Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther 1996;279: 703-12.
10. Wirth K, Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991;102:774-7.
11. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-2.
12. 2 receptor antagonism on the hypotensive effects of ACE inhibition. Br J Pharmacol 1994;113:717-22.
13. Barbe F, Su JB, Guyene T, Crozatier B, Menard J, Hittinger L. Bradykinin pathway is involved in acute hemodynamic effects of enalaprilat in dogs with heart failure. Am J Physiol 1996;270:H1985-H1992.
14. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-8.
15. Wong PY, Talamo RC, Williams GH, Colman RW. Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture. J Clin Invest 1975;55:691-8.
16. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 1983;72:2115-24.
17. Fisher ND, Allan D, Kifor I, et al. Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension 1994; 23:44-51.
18. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
19. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-7.
20. 2-receptor antagonist. Br J Clin Pharmacol 1994;38:317-21.
21. Workman RJ, Sussman CR, Burkitt DW, Liddle GW. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. J Lab Clin Med 1979;93:847-56.
22. 1α by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1994;653:117-22.
23. Carretero OA, Miyazaki S, Scicli AG. Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril. Hypertension 1981;3:18-22.
24. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21. [Erratum, N Engl J Med 1994;330:1689.]
25. Goldberg A, Sweet C. Efficacy and safety of losartan. Can J Cardiol 1995;11:Suppl F:27F-32F.
26. Madeddu P, Oppes M, Rubattu S, et al. Role of renal kallikrein in modulating the antihypertensive effect of a single oral dose of captopril in normal- and low-renin essential hypertensives. J Hypertens 1987;5:645-8.
27. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982;14:Suppl 2:97S-101S.
28. Levy SB, Lilley JJ, Frigon RP, Stone RA. Urinary kallikrein and plasma renin activity as determinants of renal blood flow: the influence of race and dietary sodium intake. J Clin Invest 1977;60:129-38.
29. Iimura O, Shimamoto K, Ura N, et al. Study of the renal kallikrein-kinin system in normal and low renin subgroups of essential hypertension. J Hypertens 1984;2:S297-S299.
30. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983;308:373-6.
31. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-50.
32. Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995;25:602-9.
33. Doig JK, McFadyen RJ, Sweet CS, Reid JL. Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol 1995;25:511-7.
34. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.
35. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin aldosterone system in hypertensive patients. Hypertension 1995;25:37-46.
36. Abe K, Itoh T, Imai Y, et al. Implication of endogenous prostaglandin system in the and hypertensive effect of captopril, SQ 14225, in low renin hypertension. Jpn Circ J 1980;44:422-5.
37. Vander AJ, Geelhoed GW. Inhibition of renin secretion by angiotensin II. Proc Soc Exp Biol Med 1965;120:399-403.
38. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995;92:825-34.
39. 2 into the renal artery of anesthetized dogs. Prostaglandins 1978;15: 81-8.
40. Beierwaltes WH. Prostaglandin independence of kinin-stimulated renin release. Am J Physiol 1987;252:F794-F799.
41. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16:564-72.
42. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50.